|
1.
|
総説
|
薬剤性肺障害：最新の治療薬に伴う肺毒性の診断とマネジメント 2026/10
|
|
2.
|
原著(症例報告除く)
|
Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer 2026/09
|
|
3.
|
原著(症例報告除く)
|
Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab 2026/08
|
|
4.
|
原著(症例報告除く)
|
Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan 2026/08
|
|
5.
|
原著(症例報告除く)
|
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis 2026/08
|
|
6.
|
原著(症例報告除く)
|
High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L) 2026/07
|
|
7.
|
原著(症例報告除く)
|
Long-Term Nationwide Post-Marketing Surveillance Cohort Study of Nivolumab in Advanced Non-Small-Cell Lung Cancer 2026/07
|
|
8.
|
その他
|
Should supportive care be started before initiating cancer treatment? 2026/07
|
|
9.
|
原著(症例報告除く)
|
AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer. 2026/05
|
|
10.
|
総説
|
【特発性間質性肺炎を再考する-StandardとUnmet medical needs】Unmet medical needs ILDの合併症と治療 間質性肺疾患合併肺癌 2026/05
|
|
11.
|
総説
|
【肺癌診療のアップデート】 切除可能非小細胞肺癌に対する周術期治療（ALK融合遺伝子、EGFR遺伝子変異、その他のドライバー変異） 2026/05
|
|
12.
|
原著(症例報告除く)
|
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan 2026/04
|
|
13.
|
総説
|
Survival, Toxicity, and Sequencing: Navigating the New First-Line Standard Established by FLAURA2 2026/04
|
|
14.
|
原著(症例報告除く)
|
Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan 2026/02
|
|
15.
|
総説
|
【ここが変わった!-呼吸器診療 最新スタンダード】肺腫瘍 小細胞肺癌 2026/02
|
|
16.
|
原著(症例報告除く)
|
Cemiplimab in Japanese patients with advanced non-small cell lung cancer 2026/01
|
|
17.
|
原著(症例報告除く)
|
Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study. 2026/01
|
|
18.
|
総説
|
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology 2026/01
|
|
19.
|
原著(症例報告除く)
|
Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small cell lung cancer and interstitial lung disease: A multicenter retrospective study 2026
|
|
20.
|
原著(症例報告除く)
|
Multicenter real-world data on first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer and performance status 2: WJOG18424L 2025/12
|
|
21.
|
原著(症例報告除く)
|
Incidence and risk factors of unilateral upper-lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis after lung cancer surgery in interstitial lung disease patients. Respir Investig. 2025/09
|
|
22.
|
原著(症例報告除く)
|
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L) 2025/08
|
|
23.
|
原著(症例報告除く)
|
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 2025/06
|
|
24.
|
原著(症例報告除く)
|
High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study 2025/05
|
|
25.
|
総説
|
間質性肺炎と肺がんのMDD 専門家チームで進める“最適化” 2025/05
|
|
26.
|
症例報告
|
Trapped Lung as a Sequela of Dramatic Tumor Shrinkage of Lung Cancer 2025/02
|
|
27.
|
原著(症例報告除く)
|
Survival Benefit and Potential Markers of Chemotherapy for Elderly and Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry Database 2025
|
|
28.
|
総説
|
【あらためて考える—肺癌周術期治療 課題とこれから】Ⅵ. ドライバー遺伝子変異/転座を有する非小細胞肺癌の周術期治療 EGFR遺伝子変異陽性非小細胞肺癌に対する周術期治療 2025
|
|
29.
|
原著(症例報告除く)
|
患者・医師アンケート2023から見えてくる、肺がん治療と仕事の両立支援のいま 2025
|
|
30.
|
総説
|
高度に専門化する肺がん診療にどんと構えるために チーム医療、共同意思決定、薬の選び方 2025
|
|
31.
|
原著(症例報告除く)
|
Clinical characteristics of pulmonary Mycobacterium avium complex disease in patients with interstitial lung disease 2024
|
|
32.
|
原著(症例報告除く)
|
Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study 2024
|
|
33.
|
原著(症例報告除く)
|
Favorable treatment response of bevacizumab-combined chemotherapy for advanced or recurrent invasive mucinous adenocarcinoma of the lung: A retrospective observational study 2024
|
|
34.
|
症例報告
|
Hypersensitivity pneumonitis with Paecilomyces as suspected inciting antigen 2024
|
|
35.
|
総説
|
KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia 2024
|
|
36.
|
原著(症例報告除く)
|
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis 2024
|
|
37.
|
原著(症例報告除く)
|
Patient-Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer in Japan 2024
|
|
38.
|
原著(症例報告除く)
|
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non- small Cell Lung Cancer: TORG1937 (DATE Study) 2024
|
|
39.
|
原著(症例報告除く)
|
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND) 2024
|
|
40.
|
原著(症例報告除く)
|
Real- World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101) 2024
|
|
41.
|
原著(症例報告除く)
|
Safety and Efficacy of Single- Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia 2024
|
|
42.
|
総説
|
Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis 2024
|
|
43.
|
総説
|
【間質性肺疾患の急性増悪をとらえなおす】原因をともなう急性増悪の頻度と予防 免疫チェックポイント阻害剤 2024
|
|
44.
|
総説
|
ガイドライン・インフォメーション-肺癌診療ガイドライン ドライバー遺伝子変異陰性非小細胞肺癌のPD-L1発現ごとの治療法 2024
|
|
45.
|
原著(症例報告除く)
|
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma 2023/11
|
|
46.
|
原著(症例報告除く)
|
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L) 2023
|
|
47.
|
原著(症例報告除く)
|
A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib 2023
|
|
48.
|
原著(症例報告除く)
|
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single- Arm Phase II Trial 2023
|
|
49.
|
原著(症例報告除く)
|
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer 2023
|
|
50.
|
原著(症例報告除く)
|
High prevalence of upper lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis in patients with round atelectasis 2023
|
|
51.
|
原著(症例報告除く)
|
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study 2023
|
|
52.
|
原著(症例報告除く)
|
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101) 2023
|
|
53.
|
症例報告
|
Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report 2023
|
|
54.
|
原著(症例報告除く)
|
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L) 2022
|
|
55.
|
原著(症例報告除く)
|
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study 2022
|
|
56.
|
原著(症例報告除く)
|
Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy 2022
|
|
57.
|
総説
|
Immune Checkpoint Inhibitor- Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: Really Mild and Easily Manageable? 2022
|
|
58.
|
原著(症例報告除く)
|
Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination 2022
|
|
59.
|
総説
|
Letter comments on anti- PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study 2022
|
|
60.
|
原著(症例報告除く)
|
Palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective 2022
|
|
61.
|
総説
|
Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer? 2022
|
|
62.
|
総説
|
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation. 2022
|
|
63.
|
総説
|
Prognosis of IPF patients with comorbid lung cancer: Preventing immortal time bias will make the analysis more valuable 2022
|
|
64.
|
原著(症例報告除く)
|
Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration 2022
|
|
65.
|
原著(症例報告除く)
|
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC 2022
|
|
66.
|
原著(症例報告除く)
|
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR 2022
|
|
67.
|
総説
|
間質性肺疾患合併進行期非小細胞肺癌における免疫チェックポイント阻害薬の投与について 長期生存をもたらしうるが、肺臓炎リスクが高く患者選択が重要 2022
|
|
68.
|
原著(症例報告除く)
|
特発性肺線維症を合併した切除不能な小細胞肺癌に対するカルボプラチン+エトポシド+ニンテダニブ併用療法の第II相試験 2022
|
|
69.
|
原著(症例報告除く)
|
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 2021/06
|
|
70.
|
原著(症例報告除く)
|
A Real- World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC 2021
|
|
71.
|
原著(症例報告除く)
|
A spectrum of Thymic mucosa-associated lymphoid tissue lymphoma and Thymic amyloidosis in the patient with Auto immune disease: a case series 2021
|
|
72.
|
原著(症例報告除く)
|
Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity 2021
|
|
73.
|
原著(症例報告除く)
|
Clinical characteristics of Japanese patients with moderate to severe COVID-19 2021
|
|
74.
|
原著(症例報告除く)
|
Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study 2021
|
|
75.
|
総説
|
Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia 2021
|
|
76.
|
原著(症例報告除く)
|
Identification and Characteristics of Co-isolation of Multiple Nontuberculous Mycobacteria 2021
|
|
77.
|
原著(症例報告除く)
|
Impact of interstitial pneumonia complications on palliative medication for terminal lung cancer: A single-center retrospective study 2021
|
|
78.
|
原著(症例報告除く)
|
Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer 2021
|
|
79.
|
原著(症例報告除く)
|
Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection 2021
|
|
80.
|
原著(症例報告除く)
|
Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease. 2021
|
|
81.
|
総説
|
Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis 2021
|
|
82.
|
原著(症例報告除く)
|
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L 2021
|
|
83.
|
原著(症例報告除く)
|
Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody 2021
|
|
84.
|
原著(症例報告除く)
|
Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019 2021
|
|
85.
|
原著(症例報告除く)
|
Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors 2021
|
|
86.
|
総説
|
【間質性肺炎 徹底討論!-鳥からは逃げられない過敏性肺炎,放置してよいのかILA】間質性肺炎合併肺癌 2021
|
|
87.
|
原著(症例報告除く)
|
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis 2020
|
|
88.
|
原著(症例報告除く)
|
A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study 2020
|
|
89.
|
症例報告
|
Anterior Mediastinal Amyloidosis Mimics Thymic Carcinoma 2020
|
|
90.
|
原著(症例報告除く)
|
Clinical, radiological, and pathological features of anti- asparaginyl tRNA synthetase antibody-related interstitial lung disease 2020
|
|
91.
|
原著(症例報告除く)
|
Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren's syndrome in transbronchial lung cryobiopsy 2020
|
|
92.
|
原著(症例報告除く)
|
Importance of doctor-initiated management of the balance between work and treatment for lung cancer patients: Results of a nationwide survey by the Japan Lung Cancer Society 2020
|
|
93.
|
症例報告
|
Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report 2020
|
|
94.
|
原著(症例報告除く)
|
Outcome of early- stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases 2020
|
|
95.
|
原著(症例報告除く)
|
Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous- cell lung cancer: TORG1322 2020
|
|
96.
|
症例報告
|
Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors 2020
|
|
97.
|
原著(症例報告除く)
|
Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis 2020
|
|
98.
|
症例報告
|
Small-cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report 2020
|
|
99.
|
原著(症例報告除く)
|
Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis 2020
|
|
100.
|
原著(症例報告除く)
|
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834) 2020
|
|
101.
|
原著(症例報告除く)
|
Unilateral upper lung-field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis after thoracic surgery: Clinical and radiological courses with autopsy findings 2020
|
|
102.
|
原著(症例報告除く)
|
患者・医師アンケートから浮き彫りになった、医師主導で行う就労を意識した肺癌マネージメントの重要性 2020
|
|
103.
|
症例報告
|
Erdheim-Chester disease progression from miliary pulmonary nodules to large tumours 2019
|
|
104.
|
原著(症例報告除く)
|
Low starting-dosage of nintedanib for the reduction of early termination 2019
|
|
105.
|
原著(症例報告除く)
|
Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis 2019
|
|
106.
|
原著(症例報告除く)
|
Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome 2019
|
|
107.
|
症例報告
|
Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case 2019
|
|
108.
|
症例報告
|
Rapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report 2019
|
|
109.
|
原著(症例報告除く)
|
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia 2019
|
|
110.
|
原著(症例報告除く)
|
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer 2018
|
|
111.
|
症例報告
|
Desquamative Interstitial Pneumonia Complicated with IgG4-related Lung Disease 2018
|
|
112.
|
原著(症例報告除く)
|
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? 2018
|
|
113.
|
原著(症例報告除く)
|
Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti- synthetase syndrome 2018
|
|
114.
|
症例報告
|
Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report 2018
|
|
115.
|
原著(症例報告除く)
|
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 2018
|
|
116.
|
原著(症例報告除く)
|
Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies 2018
|
|
117.
|
原著(症例報告除く)
|
Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia 2018
|
|
118.
|
症例報告
|
Pulmonary Follicular Lymphoma Showing Diffuse Micronodules Mimicking Sarcoidosis 2018
|
|
119.
|
症例報告
|
Secondary pulmonary alveolar proteinosis predominant in the transplanted lung in patients with idiopathic interstitial pneumonia: an autopsy case 2018
|
|
120.
|
総説
|
【IPF治療ガイドラインの実践活用法】慢性安定期の治療 CQ7 IPF患者にピルフェニドンとニンテダニブの併用を行うべきか? 2018
|
|
121.
|
症例報告
|
A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap Syndrome. 2017
|
|
122.
|
症例報告
|
A case of relapsed lung abscess caused by Eubacterium brachy infection following an initial diagnosis of pulmonary actinomycosis 2017
|
|
123.
|
症例報告
|
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity 2017
|
|
124.
|
原著(症例報告除く)
|
Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation 2017
|
|
125.
|
原著(症例報告除く)
|
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis 2017
|
|
126.
|
原著(症例報告除く)
|
Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status 2017
|
|
127.
|
原著(症例報告除く)
|
Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. 2017
|
|
128.
|
原著(症例報告除く)
|
Unilateral Upper Lung Field Pulmonary Fibrosis Radiologically Consistent with Pleuroparenchymal Fibroelastosis after Thoracotomy: A New Disease Entity Related to Thoracotomy 2017
|
|
129.
|
原著(症例報告除く)
|
Abundant immunoglobulin (Ig)G4-positive plasma cells in interstitial pneumonia without extrathoracic lesions of IgG4-related disease: is this finding specific to IgG4-related lung disease? 2016
|
|
130.
|
症例報告
|
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report 2016
|
|
131.
|
原著(症例報告除く)
|
Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis 2016
|
|
132.
|
原著(症例報告除く)
|
Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015 2016
|
|
133.
|
原著(症例報告除く)
|
Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience 2016
|
|
134.
|
症例報告
|
Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis 2016
|
|
135.
|
原著(症例報告除く)
|
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study 2016
|
|
136.
|
総説
|
【IgG4関連疾患の胸郭内病変をめぐって】肺のみに病変がある場合の対応 2016
|
|
137.
|
総説
|
注目の新薬 オフェブ(ニンテダニブ) 2016
|
|
138.
|
症例報告
|
Chronological assessment of airway lesions in relapsing polychondritis by positron emission tomography 2015
|
|
139.
|
原著(症例報告除く)
|
Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study 2015
|
|
140.
|
症例報告
|
Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia 2015
|
|
141.
|
原著(症例報告除く)
|
Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study 2015
|
|
142.
|
原著(症例報告除く)
|
Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split? 2015
|
|
143.
|
症例報告
|
Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case 2014
|
|
144.
|
症例報告
|
Interstitial lung disease induced by alectinib (CH5424802/RO5424802) 2014
|
|
145.
|
症例報告
|
進行性に肺胞構造の破壊をきたした特発性肺ヘモジデローシスの1成人例 2013
|
|
146.
|
症例報告
|
二度の急性増悪も早期にPMX-DHPを併用し改善が得られた特発性肺線維症の1症例 2011
|
|
5件表示
|
|
全件表示(146件)
|
